Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 03, 2024
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 19, 2023
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The paper is titled 'Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's already receiving donepezil and contains an analysis of the overall data from the Phase II clinical trial for Alzheimer's disease conducted in Korea.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GemVax & Kael Reports Further Positive Data from GV1001 Phase II Alzheimer's Disease Trial
Details : GemVax's GV1001 Phase II trial evaluated the safety and efficacy of subcutaneous injection of GV1001 0.56 mg or 1.12 mg for six months in patients with moderate-to-severe Alzheimer's disease already receiving donepezil for more than three months, at 12 m...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pivotal decision is based on an encouraging recent analysis of results from a Phase II trial of GV1001, completed last year in Korea and if granted would apply to a second Phase IIb trial in the US now planned for early 2021.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gemvax & Kael Expands GV1001 Patent To Cover COVID-19
Details : GV1001 has been proven to relieve the aforementioned conditions, as well as help boost immune system, in the preclinical trial phase.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finasteride
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2019
Lead Product(s) : Finasteride
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 22, 2019